Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 10.12M | 1.70M | 6.19M | 2.33M | 242.00K |
Gross Profit | -1.27M | -4.87M | -131.03M | -126.32M | -134.65M |
EBITDA | -182.42M | -156.77M | -135.54M | -132.01M | -160.51M |
Net Income | -220.66M | -208.38M | -148.84M | -142.10M | -142.09M |
Balance Sheet | |||||
Total Assets | 782.73M | 375.38M | 490.27M | 405.56M | 294.24M |
Cash, Cash Equivalents and Short-Term Investments | 588.02M | 239.57M | 382.44M | 310.34M | 153.30M |
Total Debt | 52.63M | 52.97M | 24.26M | 21.00M | 54.16M |
Total Liabilities | 355.40M | 263.91M | 191.60M | 92.24M | 84.20M |
Stockholders Equity | 427.32M | 111.47M | 298.67M | 313.32M | 210.03M |
Cash Flow | |||||
Free Cash Flow | -241.09M | -156.57M | -123.15M | -126.72M | -132.44M |
Operating Cash Flow | -206.27M | -145.59M | -112.31M | -117.86M | -117.76M |
Investing Cash Flow | -394.55M | -10.99M | -10.84M | -8.86M | -14.68M |
Financing Cash Flow | 589.55M | -883.00K | 223.61M | 284.06M | 74.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | $463.04M | ― | -48.98% | ― | -9.95% | 20.78% | |
54 Neutral | $641.40M | ― | -49.91% | ― | -14.16% | 25.88% | |
52 Neutral | $7.46B | -0.04 | -63.82% | 2.49% | 16.43% | <0.01% | |
51 Neutral | $340.65M | ― | -57.28% | ― | -95.12% | 21.09% | |
45 Neutral | $474.72M | ― | -26.14% | ― | ― | 74.59% | |
44 Neutral | $535.79M | ― | -33.14% | ― | ― | ― | |
44 Neutral | $514.60M | ― | -115.39% | ― | ― | -4.14% |
On June 26, 2025, Autolus Therapeutics held its Annual General Meeting where all nine proposed resolutions were passed. Key resolutions included the adoption of the 2024 Annual Report, approval of the Directors’ remuneration report and policy, re-appointment of Ernst & Young LLP as auditors, re-election of Dr. R Iannone and Dr. R Rao as Directors, and the approval of the Employee Share Purchase Plan.
The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
On June 2, 2025, Autolus Therapeutics plc released its UK Annual Report and Accounts for the year ending December 31, 2024, and announced its upcoming annual general meeting scheduled for June 26, 2025. Citibank, as the depositary bank for Autolus’s American Depositary Shares, began distributing voting materials to ADS holders, allowing them to instruct the bank on voting their shares, although there may be limitations affecting timely voting.
The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy announced their decision not to seek re-election to the Board of Directors of Autolus Therapeutics at the upcoming Annual General Meeting. Their resignation is not due to any disagreements with the company’s management or board, suggesting a smooth transition and stability within the company’s governance structure.
The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Autolus Therapeutics reported its financial results for the first quarter of 2025, highlighting a net product revenue of $9.0 million from AUCATZYL® and securing marketing authorization from the U.K.’s MHRA. The company is advancing its clinical trials, including a Phase 2 trial for lupus nephritis and a Phase 1 trial for multiple sclerosis, with plans to dose the first patients by the end of 2025. Despite a net loss of $70.2 million for the quarter, Autolus remains well-capitalized to support its ongoing and planned clinical developments, aiming to expand its therapeutic reach and address significant unmet medical needs.
On April 23, 2025, Autolus Therapeutics will present a corporate update at an R&D investor event, which will be accessible via a live webcast and archived on the company’s website. This presentation may impact the company’s operations and industry positioning by providing stakeholders with insights into its ongoing research and development efforts.